BofA Securities Downgrades Neumora Therapeutics (NMRA) to Underperform
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad downgraded Neumora Therapeutics (NASDAQ: NMRA) from Buy to Underperform with a price target of $1.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
